Biomarker
OwnerSusan GREENFIELD, Henry TU +3inventors
InventorsSusan GREENFIELD, Henry TU, Paul MORRILL, Sergio ROTONDO, Sara GARCIA-RATES
Life of this patent
Estimating the term…
Abstract
The invention relates to biomarkers for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease or Motor Neurone disease. The invention especially relates to a novel quantitative predictive biomarker for cognitive decline, and in particular the rate of cognitive decline that a subject will suffer, for example as a result of developing a neurode-generative disorder. The invention further provides diagnostic and prognostic methods, and kits for predicting the rate of cognitive decline in subjects.
Claims22
A method for predicting the rate at which a subject will suffer from cognitive decline, or for detecting a pre-disposition thereto, the method comprising:
- (a) analysing, in a sample obtained from a test subject, the concentration of (i) a soluble peptide comprising or consisting of SEQ ID No:3, or a variant or fragment thereof and/or
- (ii) an aggregated peptide comprising or consisting of SEQ ID No:3, or a variant or fragment thereof;
- and
- (b) comparing this concentration with a reference value from a control population for concentrations of either soluble or aggregated peptide comprising or consisting of SEQ ID No:3, or a variant or fragment thereof,
- wherein a lower concentration of soluble peptide comprising or consisting of SEQ ID No:3, or a variant or fragment thereof, and/or a higher concentration of aggregated peptide comprising or consisting of SEQ ID No:3, from the test subject, relative to the respective reference value, suggests that the subject will suffer from a higher rate of cognitive decline, or has a pre-disposition thereto.
(canceled)
19-24. (canceled)
A method of treating a subject prone to suffering from cognitive decline, or having a pre-disposition thereto, the method comprising:
- (a) analysing, in a sample obtained from the subject, the concentration of (i) a soluble peptide comprising or consisting of SEQ ID No:3, or a variant or fragment thereof and/or (ii) an aggregated peptide comprising or consisting of SEQ ID No:3, or a variant or fragment thereof, wherein a lower concentration of soluble peptide comprising or consisting of SEQ ID No:3, or a variant or fragment thereof, and/or a higher concentration of aggregated peptide comprising or consisting of SEQ ID No:3, from the test subject, relative to a respective reference value from a control population for concentrations of either soluble or aggregated peptide comprising or consisting of SEQ ID No:3, or a variant or fragment thereof, suggests that the subject will suffer from a higher rate of cognitive decline, or has a pre-disposition thereto;
- and
- (b) administering, to the subject, a therapeutic agent that prevents, reduces or delays cognitive decline.
Dependencies are inferred from the claim text.